Cancer discovery news
Our researchers are making the discoveries that defeat cancer. Read the latest findings from our world-leading research.
Visit our main news hub to read about news on new funding, our fundraising activities and much more. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Powerful new therapy doubles progression-free survival in advanced breast cancer
A three-drug combination for aggressive advanced breast cancer doubles the length of time before the cancer progresses, compared with a drug combination currently available on the NHS, new research has shown.
More than £5 million secured for the ICR from Cancer Research UK’s RadNet programme to fund work in radiotherapy
Cancer Research UK (CRUK) has awarded The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust a substantial £5.14 million through its radiation research network (RadNet) to support pioneering research in radiation therapy.
New imaging technique could spot patients with aggressive brain tumours who would benefit from immunotherapy
A new imaging technique could mean patients with aggressive glioblastomas benefit from cutting edge immunotherapy treatments, according to researchers.
-1.jpg?sfvrsn=3efe4a5_2 "Glioblastoma (Dr Chris Jones/the ICR)-1")
World's first trial to test multiple treatments for brain cancers
A pioneering research study which will allow brain cancer patients to access drugs that are precisely targeted to their disease and swap to different treatments if needed, has launched in the UK.
£1.5m AI and genetics project to find men with deadliest prostate cancers early
Doctors could predict whether a man’s prostate cancer will be aggressive at the point of diagnosis – giving him the best targeted treatment quickly before it spreads – thanks to a new £1.5 million research project harnessing artificial intelligence and cutting-edge genetic analysis.
New drug combination offers hope to women with rare treatment-resistant ovarian cancer
A combination of two drugs which can block the growth of cancer cells has shown promising results in women with a form of ovarian cancer that rarely responds to chemotherapy or hormone therapy.
Higher doses of radiotherapy cuts treatment time by 75% in localised prostate cancer patients, while maintaining high cure rates
People with intermediate risk, localised prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, according to researchers from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust.
Prostate cancer spit test could save the NHS £500 million a year
Thousands of men could have their prostate cancer diagnosed at an earlier stage when it is easier and cheaper to treat, thanks to a new spit test which can be taken at home.
Multi-million-pound UK-wide platform into cancer immunotherapy launches
A new multimillion-pound research programme, involving scientists from The Institute of Cancer Research, London, is aiming to discover why at least half of all patients fail to respond to immunotherapy or suffer from debilitating side effects.
Personalised radiotherapy for people with bladder cancer shows promise
Researchers are a step closer to revolutionising how doctors use radiotherapy to treat patients with muscle-invasive bladder cancer.
New genetic testing pathways could ensure patients get personalised treatments and help to catch more BRCA-linked cancer cases
Scientists have developed a new clinical pathway for testing for the cancer-causing faults in the BRCA gene that could ensure patients get the right treatment and boost the number of people who get tested.
Dave Day raises more than £63,000 for The Institute of Cancer Research
A charity fundraising event that was set up as a tribute to Dave Myers, the much-loved TV chef, raised an incredible £63,169.32 for The Institute of Cancer Research, London.